Phase II randomized study of Fianlimab plus Cemiplimab versus Cemiplimab plus placebo in first-line treatment of participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) that is positive for PD-L1 expression
Phase: Phase III clinical trials
Principal Investigator: Professoressa Associata Licitra Lisa Francesca Linda
Main Facility: Oncologia Medica 3 - Tumori testa-collo
Drug: REGN3767 - REGN2810
Pathologies: Head and neck cancers
ClinicalTrials.gov: Read the details about clinical trials
Head and neck cancer is the seventh leading cancer by incidence worldwide with the diagnosis of approximately 890,000 new cases annually.
CC of the head and neck constitute 90% of all HNCs and are the ninth leading cancer by incidence worldwide.
For participants with R/M HNSCC, the disease is almost uniformly fatal despite intervention with standard treatments such as the anti-PD-1 antibody pembrolizumab with or without chemotherapy.
In 1L R/M HNSCC participants with tumors that express PD-L1 CPS ≥1, dual blockade of the LAG-3 and PD-1 immune checkpoints, with fianlimab and cemiplimab may result in a higher ORR than blockade of the PD-1 immune checkpoint with cemiplimab alone.
Fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) are both high-affinity, human, mhinge-stabilized immunoglobulin G4 monoclonal antibodies. Fianlimab (REGN3767) blocks LAG-3 / major histocompatibility complex class II-driven T-cell inhibition. Cemiplimab m(REGN2810, LIBTAYO®) blocks interactions of PD-1 with PD-L1 and PD-L2.
The current study will further investigate cemiplimab with or without fianlimab with the hypothesis that the combination will have additive or synergistic effects that may provide clinical benefit in participants with 1L R/M HNSCC, with PD-L1 CPS ≥1.
This is a randomized, multicenter, phase 2 study in participants with R/M HNSCC to be treated with immunotherapy in the 1L setting.
Approximately 120 participants will be enrolled in the study across 2 cohorts:
• Cohort 1 (60 participants, HPV positive HNSCC) randomized 1:1 into:
− Fianlimab (1600 mg IV Q3W) + Cemiplimab (350 mg IV Q3W)
− Placebo (IV Q3W) + Cemiplimab (350 mg IV Q3W)
• Cohort 2 (60 participants, HPV negative HNSCC) randomized 1:1 into:
− Fianlimab (1600 mg IV Q3W) + Cemiplimab (350 mg IV Q3W)
− Placebo (IV Q3W) + Cemiplimab (350 mg IV Q3W)
Visit frequency is D1 of every cycle. Each cycle is 3 weeks in duration.
The PD-L1 CPS score for all study participants must be ≥1 (per previously documented test result obtained prior to screening).
Participants and investigators will be blinded to treatment assignment. The study pharmacist will not be blinded to treatment assignment. The pharmacist will be unblinded to allow for preparation of study interventions. The sponsor may be unblinded in order to perform milestone data snapshots and analyses.
The primary objective is to evaluate investigator-assessed ORR with
combination therapy (fianlimab + cemiplimab) vs cemiplimab monotherapy
(cemiplimab + placebo) in participants with HNSCC.
The secondary objective is to evaluate the safety and tolerability of the
combination vs cemiplimab, evaluate the DCR of the combination vs
cemiplimab, evaluate the DOR of the combination vs
cemiplimab, evaluate the PFS of the combination vs cemiplimab, to caracterize PK of fianlimab and cemiplimab and to assess the immunogeni city of fianlimab.
This study is comprised of a Screening period, Treatment period, and Follow-up period as follows:
• Screening period: within a period of not more than 28 days prior to randomization.
• Treatment period: for a duration of approximately 2 years/36 cycles.
• Follow-up period: after completion of treatment phase, participants (who do not enter survival follow-up or end of study) will have a follow-up visit 90 days after last study dose. In addition, participants will be contacted by phone every quarter for serviva follow-up.
Last update: 10/11/2026